Literature DB >> 19175387

Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours.

Frank W Drislane1, Andrew S Blum, Maria R Lopez, Shiva Gautam, Donald L Schomer.   

Abstract

PURPOSE: Outcome for patients with status epilepticus (SE) depends strongly on etiology. Duration of SE is also predictive, at least in the first 2 h, but beyond this it is unclear that duration of SE influences outcome significantly. We sought to determine the influence of duration of SE on outcome in patients with prolonged SE, and to compare this influence with that of other factors.
METHODS: We reviewed the clinical course and outcome of 119 patients with SE, diagnosed by both clinical manifestations and electroencephalography (EEG) evidence. Using univariate and multivariate analyses, we sought predictors of outcome (survival vs. death or vegetative state) among age, etiology (epilepsy, anoxia or severe hypoxia, or other), presence of earlier epilepsy, multiple medical problems, presentation in coma, and type of SE (focal or generalized).
RESULTS: Median duration of SE was 48 h. Survival was greater with a shorter duration, especially when <10 h (69% vs. 31% for longer duration; p < 0.05). Epilepsy as the etiology, and an earlier diagnosis of epilepsy offered a favorable prognosis (p < 0.01), but only the former on multivariate analysis. Coma and SE caused by anoxia/hypoxia were unfavorable factors. Once corrected for etiology, presentation in coma, and type of SE (focal or generalized), duration of SE did not have a significant effect on outcome. Overall mortality was high, 65%, but 10 patients survived SE lasting over 3.5 days.
CONCLUSIONS: A duration of <10 h was associated with better outcome in SE, but this was not significant once etiology, presentation in coma, and type of SE were accounted for. Etiology of SE is still the primary determinant of outcome. Unless it follows anoxia, prolonged SE should not be considered a hopeless condition.

Entities:  

Mesh:

Year:  2009        PMID: 19175387     DOI: 10.1111/j.1528-1167.2008.01993.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  37 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

2.  Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus.

Authors:  Nicholas Johnson; Craig Henry; A James Fessler; Josep Dalmau
Journal:  Neurology       Date:  2010-09-08       Impact factor: 9.910

Review 3.  Refractory and super-refractory status epilepticus--an update.

Authors:  Sara Hocker; William O Tatum; Suzette LaRoche; W David Freeman
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

4.  Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicenter comparison.

Authors:  Vincent Alvarez; Jong Woo Lee; Frank W Drislane; M Brandon Westover; Jan Novy; Barbara A Dworetzky; Andrea O Rossetti
Journal:  Epilepsia       Date:  2015-07-03       Impact factor: 5.864

5.  Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study.

Authors:  Annalena Hottinger; Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2012-09-01       Impact factor: 5.749

6.  Association of seizure duration and outcome in refractory status epilepticus.

Authors:  Dominik Madžar; Anna Geyer; Ruben U Knappe; Stephanie Gollwitzer; Joji B Kuramatsu; Stefan T Gerner; Hajo M Hamer; Hagen B Huttner
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

7.  Therapeutic coma for status epilepticus: Differing practices in a prospective multicenter study.

Authors:  Vincent Alvarez; Jong Woo Lee; M Brandon Westover; Frank W Drislane; Jan Novy; Mohamed Faouzi; Nicola A Marchi; Barbara A Dworetzky; Andrea O Rossetti
Journal:  Neurology       Date:  2016-09-24       Impact factor: 9.910

8.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

9.  Intravenous anesthesia in treatment of nonconvulsive status epilepticus: Characteristics and outcomes.

Authors:  Utku Uysal; Mark Quigg; Brennen Bittel; Nancy Hammond; Theresa I Shireman
Journal:  Epilepsy Res       Date:  2015-07-26       Impact factor: 3.045

10.  Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus.

Authors:  Matthew Ferguson; Matt T Bianchi; Raoul Sutter; Eric S Rosenthal; Sydney S Cash; Peter W Kaplan; M Brandon Westover
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.